Appetite signaling: From gut peptides and enteric nerves to brain

Physiology and Behavior

Volumn 92, Issue 1-2, 2007, Pages 256-262

  Näslund, Erik ^a   Hellström, Per M ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Food intake; Gastric emptying; Gastrointestinal; Hunger; Peptides; Satiety

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA MELANOCORTIN STIMULATING HORMONE; CHOLECYSTOKININ; GASTROINTESTINAL POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; MELANOCORTIN; NEUROPEPTIDE; NEUROPEPTIDE Y; OREXIN; OXYNTOMODULIN; PEPTIDE YY; UNCLASSIFIED DRUG;

APPETITE; ARCUATE NUCLEUS; ENTEROENDOCRINE CELL; FEEDING BEHAVIOR; FOOD INTAKE; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; INTESTINE INNERVATION; LEAN BODY WEIGHT; METABOLIC REGULATION; MOTOR ACTIVITY; NERVE CELL NETWORK; NEUROPHYSIOLOGY; NEUROTRANSMISSION; OBESITY; PRIORITY JOURNAL; REVIEW; SATIETY; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS;

EID: 34548473376     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2007.05.017     Document Type: Review

References (83)

1. MacDougald O.A., and Mandrup S. Adipogenesis: forces that tip the scales. Trends Endocrinol Metab 13 (2002) 5-11
2. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
3. Read N.W., French S., and Cunningham K. The role of the gut in regulating food intake in man. Nutr Rev 52 (1994) 1-10
4. Schwartz G.J., McHugh P.R., and Moran T.H. Gastric loads and cholecystokinin synergistically stimulate rat gastric vagal afferents. Am J Physiol 265 (1993) R872-R876
5. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
6. Tschöp M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
7. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86 (2001) 5992-5995
8. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., and Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50 (2001) 1714-1719
9. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123 (2002) 1120-1128
10. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., et al. A role for ghrelin in the central regulation of feeding. Nature 409 (2001) 194-198
11. Tschöp M., Viswanath D., Weyer C., Tataranni P.A., Ravussin E., and Meimann M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001) 707-709
12. Shiiya T., Nakazato M., Mizuta M., Date Y., Mondal M.S., Tanaka M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87 (2002) 240-244
13. Edholm T., Levin F., Hellström P.M., and Schmidt P.T. Ghrelin stimulates motility in the small intestine through intrinsic cholinergic neurons. Regul Pept 121 (2004) 25-30
14. Levin F., Edholm T., Ehrström M., Wallin B., Schmidt P.T., Kirchgessner A.M., et al. Effect of peripherally administered ghrelin on gastric emptying and acid secretion in the rat. Regul Pept Nov 131 (2005) 59-65
15. Dass N.B., Munonyara M., Bassil A.K., Hervieu G.J., Osbourne S., Corcoran S., et al. Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience 120 (2003) 443-453
16. Ritter R.C., Covasa M., and Matson C.A. Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Neuropeptides 33 (1999) 387-399
17. Buchan A.M., Polak J.M., Solcia E., Capella C., Hudson D., and Pearse A.G. Electron immunohistochemical evidence for human intestinal I cells as the source of CCK. Gut 19 (1978) 403-407
18. Kissileff H.R., Pi-Sunyer X., Thornton J., and Smith G.P. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34 (1981) 154-160
19. Ballinger A., McLoughlin L., Medback S., and Clark M. Cholecystokinin is a satiety hormone in humans at physiological post-prandial concentrations. Clin Sci 89 (1995) 375-381
20. Lieverse R.J., Jansen J.B., Masclee A.A., and Lamers C.B. Satiety effects of a physiological dose of cholecystokinin in humans. Gut 36 (1995) 176-179
21. Reubi J.C., Waser B., Läderach U., Stettler C., Friess H., Halter F., et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 112 (1997) 1197-1205
22. Mercer J.G., and Lawrence C.B. Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365260, for axonally-transported CCK binding sites on the rat vagus nerve. Neurosci Lett 137 (1992) 229-231
23. French S.J., Murry B., Rumsey R.D., Sepple C.P., and Read N.W. Is cholecystokinin a satiety hormone? Correlations of plasma cholecystokinin with hunger, satiety, and gastric emptying in normal volunteers. Appetite 21 (1991) 95-104
24. Bell G.I., Santerre R.F., and Mullenbach G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302 (1983) 716-718
25. Holst J.J. Enteroglucagon. Annu Rev Physiol 59 (1997) 257-271
26. Näslund E., Bogefors J., Skogar S., Grybäck P., Jacobsson H., Holst J.J., et al. Glucagon-like peptide-1 slows solid gastric emptying with inhibition of insulin, C-peptide, glucagon and peptide YY release in humans. Am J Physiol 277 (1999) R910-R916
27. Ørskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 35 (1992) 701-711
28. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., and Holst J.J. Truncated GLP-1 (proglucagon 87-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38 (1993) 665-673
29. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Ørskov C., Ritzel R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273 (1997) E981-E988
30. Wettergren A., Wøjdemann M., Meisner S., Stadil F., and Holst J.J. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretions in humans depends on an intact vagal innervation. Gut 40 (1997) 597-601
31. Wettergren A., Wøjdemann M., and Holst J.J. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275 (1998) G984-G992
32. Imeryüz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva-Penacarrillo M.L., and Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273 (1997) G920-G927
33. Tolessa T., Gutniak M., Holst J.J., Efendic S., and Hellström P.M. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43 (1998) 2284-2290
34. 2 in the central control of feeding behaviour. Digestion 54 (1994) 360-361
35. Tang-Christensen M., Larsen P.J., Göke R., Fink-Jensen A., Jessop D.S., Møller M., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271 (1996) R848-R856
36. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M.B., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 385 (1996) 69-72
37. Bloom S.R. Glucagon-like peptide-1 and satiety. Nature 385 (1997) 214
38. Ranganath L.R., Beety J.-.M., Morgan L.M., Wright J.W., Howland R., and Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence. Gut 38 (1996) 916-919
39. Näslund E., Grybäck P., Backman L., Jacobsson H., Holst J.J., Theodorsson E., et al. Small bowel gut hormones: correlation to fasting antroduodenal motility and gastric emptying. Dig Dis Sci 43 (1998) 945-952
40. Ranganath L., Norris F., Morgan L., Wright J., and Marks V. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci 96 (1999) 335-342
41. Näslund E., Gutniak M., Skogar S., Rössner S., and Hellström P.M. Glucagon-like peptide-1 (GLP-1) increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68 (1998) 525-530
42. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
43. Näslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 in obese men. Int J Obes Relat Metab Disord 23 (1999) 304-311
44. Näslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., et al. Glucagon-like peptide-1 decreases feelings of hunger and suppresses energy intake in obese humans. Int J Obes Relat Metab Disord 23 (1999) 304-311
45. Gutzwiller J.P., Drewe J., Göke B., Schmidt H., Rohrer B., Lareida J., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276 (1999) R1541-R1544
46. Gutzwiller J.P., Göke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44 (1999) 81-86
47. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide-1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
48. Flint A., Raben A., Rehfeld J.F., Holst J.J., and Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 24 (2000) 288-298
49. Tsai C.H., Hill M., and Drucker D.J. Biological determinants of intestinotrophic properties of GLP-2. Am J Physiol 272 (1997) G662-G668
50. Lovshin J., and Drucker D.J. New frontiers in the biology of GLP-2. Regul Pept 90 (2000) 27-32
51. Schmidt P.T., Näslund E., Grybäck P., Jacobsson H., Hartmann B., Holst J.J., et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 116 (2003) 21-25
52. Sørensen L.B., Flint A., Raben A., Hartmann B., Holst J.J., and Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 27 (2003) 450-456
53. Wynne K., Park A.J., Small C.J., Patterson M., Ellis A.M., Murphy K.G., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects. Diabetes 54 (2005) 2390-2395
54. Batterham R.L. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418 (2002) 650-654
55. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 (2003) 941-948
56. Tschöp M., Castaneda T.R., Joost H.G., Thone-Reineke C., Ortmann S., Klaus S., et al. Physiology: does gut hormone PYY3-36 decrease food intake in rodents?. Nature 430 (2004) 1 p following 165; discussion 2 p following 165. Erratum in: Nature 2004, 431:1038.""
57. Al-Saffar A., Hellström P.M., and Nylander G. Correlation between peptide YY-induced myoelectric activity and transit of small-intestinal contents in rats. Scand. J. Gastroenterol 20 (1985) 577-582
58. Savage A.P., Adrian T.E., Carolan G., Chatterjee V.K., and Bloom S.R. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 28 (1987) 166-170
59. Zhang J.V., Ren P.G., Avsian-Kretchmer O., Luo G.W., Rauch R., Klein C., et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310 (2005) 996-999
60. Granström L., and Backman L. Stomach distension in extremely obese and in normal subjects. Acta Chir Scand 151 (1985) 367-370
61. Geliebter A. Gastric distension and gastric capacity in relation to food intake in humans. Physiol Behav 44 (1988) 665-668
62. Mathus-Vliegen E.M. Long-term health and psychosocial outcomes from surgically induced weight loss: results obtained in patients not attending protocolled follow-up visits. Int J Obes Relat Metab Disord. 16 (2006) 1508-1519
63. Geliebter A., Schachter S., Lohmann-Walter C., Feldman H., and Hashim S.A. Reduced stomach capacity in obese subjects after dieting. Am J Clin Nutr 63 (1996) 170-173
64. Brolin R.E. Critical analysis of results: weight loss and quality of data. Am J Clin Nutr 55 (1992) 577S-581S
65. Geracioti T.D., and Liddle R.A. Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med 319 (1988) 683-688
66. Näslund E., King N., Mansten S., Adner N., Holst J.J., and Gutniak M. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 91 (2004) 1-9
67. Chamorro S., Dell-Zuana O., Fauchere J.L., Feletou M., Galizzi J.P., and Levens N. Appetite suppression based on selective inhibition of NPY receptors. Int J Obes Relat Metab Disord 26 (2002) 281-298
68. Wikberg J.E., Mutulis F., Mutule I., Veiksina S., Lapinsh M., Petrovska R., et al. Melanocortin receptors: ligands and proteochemometrics modeling. Ann N Y Acad Sci 994 (2003) 21-26
69. Broberger C., Johansen J., Johansson C., Schalling M., and Hökfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci U S A 95 (1998) 15043-15048
70. Hahn T.M., Breininger J.F., Baskin D.G., and Schwartz M.W. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nature 1 (1998) 271-272
71. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
72. Jin S.L.C., Han V.K.M., Simmons J.G., Towle A.C., Lauder J.M., and Lund P.K. Distribution of glucagon-like peptide-1 (GLP-1), glucagon, and glicentin in the rat brain. J Comp Neurol 271 (1988) 519-532
73. Shimizu I., Hirota M., Ohboshi C., and Shima K. Identification and localization of the glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121 (1987) 1076-1082
74. Kreymann B., Ghatei M.A., Burnet P., Williams G., Kanse S., Diani A.R., et al. Characterization of glucagon-like peptide-1-(7-36)amide in the hypothalamus. Brain Res 502 (1989) 325-331
75. Kirchgessner A.L., and Liu M. Orexin synthesis and response in the gut. Neuron 24 (1999) 941-951
76. Näslund E., Ehrström M., Ma J., Hellström P.M., and Kirchgessner A.L. Localization and effects of orexin on fasting motility in the rat duodenum. Am J Physiol 282 (2002) G470-G479
77. Nowak K.W., Mackowiak P., Switonska M.M., Fabis M., and Malendowicz L.K. Acute orexin effects on insulin secretion in the rat: in vivo and in vitro studies. Life Sci 66 (2000) 449-454
78. Ouedrago R., Näslund E., and Kirchgessner A.L. Glucose regulates the release of orexin-a from the endocrine pancreas. Diabetes 52 (2003) 111-117
79. Komaki G., Matsumoto Y., Nishikata H., Kawai K., Nozaki T., Takii M., et al. Orexin-A and leptin change inversely in fasting non-obese subjects. Eur J Endocrinol 144 (2001) 645-651
80. Burdyga G., Lal S., Spiller D., Jiang W., Thompson D., Attwood S., et al. Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. Gastroenterology 124 (2003) 129-139
81. Hewson G., Leighton R.G., and Hughes J. The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br J Pharmacol 93 (1988) 79-84
82. Reidelberger R.D., Varga G., and Solomon T.E. Effects of selective cholecystokinin antagonists L364,718 and L365,260 on food intake in rats. Peptides 12 (1991) 1215-1221
83. Gutzwiller J.P., Degen L., Matzinger D., Prestin S., and Beglinger C. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol 287 (2004) R562-R567